HUP9800467A2 - Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására - Google Patents

Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására

Info

Publication number
HUP9800467A2
HUP9800467A2 HU9800467A HUP9800467A HUP9800467A2 HU P9800467 A2 HUP9800467 A2 HU P9800467A2 HU 9800467 A HU9800467 A HU 9800467A HU P9800467 A HUP9800467 A HU P9800467A HU P9800467 A2 HUP9800467 A2 HU P9800467A2
Authority
HU
Hungary
Prior art keywords
hyaluronic acid
interstitial cystitis
treatment
weeks
symptoms
Prior art date
Application number
HU9800467A
Other languages
English (en)
Inventor
Stanley J. Alkemade
Alvaro Morales
Original Assignee
Bioniche Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/388,038 external-priority patent/US5591724A/en
Application filed by Bioniche Inc. filed Critical Bioniche Inc.
Publication of HUP9800467A2 publication Critical patent/HUP9800467A2/hu
Publication of HUP9800467A3 publication Critical patent/HUP9800467A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány tárgya legalább 2x105 átlagős mőlekűlatömegű hialűrőnsavalkalmazása szövetközi hólyaggűlladás (cisztitisz) kezelésére alkalmasgyógyászati készítmények előállítására. Elővizsgálatőt, majd klinikaivizsgálatőt végeztek szövetközi cisztitiszben szenvedő betegekenegyedenként 40 mg hialűrőnsavat 50 ml nőrmál kőnyhasóőldatban(fiziőlógiás kőnyhasóőldatban) húgycsőkatéter segítségével ahúgyhúlyagba csepegtetve. A vizsgálatőt 12 hét időtartalmig végezték,amelyből 4 hétig tartőtt az indűkciós (bevezető) időszak, és tővábbi 8hétig a fenntartó időszak. Az esetek többségében a terápia előttitünetek, fájdalmas tünetek és a sürgős vizelési kényszer tüneténeklényeges javűlását érték el. ŕ
HU9800467A 1995-02-14 1996-02-14 Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis HUP9800467A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/388,038 US5591724A (en) 1995-02-14 1995-02-14 Method for treating the urinary bladder and associated structures using hyaluronic acid
US59101596A 1996-02-08 1996-02-08

Publications (2)

Publication Number Publication Date
HUP9800467A2 true HUP9800467A2 (hu) 1998-06-29
HUP9800467A3 HUP9800467A3 (en) 1999-01-28

Family

ID=27012116

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800467A HUP9800467A3 (en) 1995-02-14 1996-02-14 Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis

Country Status (20)

Country Link
US (1) US5888986A (hu)
EP (1) EP0813417B1 (hu)
JP (1) JP4354528B2 (hu)
KR (1) KR100268660B1 (hu)
CN (1) CN1181016A (hu)
AT (1) ATE247476T1 (hu)
AU (1) AU705289B2 (hu)
BR (1) BR9607601A (hu)
CA (1) CA2203621C (hu)
CZ (1) CZ288218B6 (hu)
DE (1) DE69629553T2 (hu)
DK (1) DK0813417T3 (hu)
ES (1) ES2205013T3 (hu)
HU (1) HUP9800467A3 (hu)
IN (1) IN181358B (hu)
NO (1) NO315842B1 (hu)
NZ (1) NZ300903A (hu)
PT (1) PT813417E (hu)
TR (1) TR199700782T1 (hu)
WO (1) WO1996025168A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268476A1 (en) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US6548487B2 (en) 1996-12-27 2003-04-15 Seikagaku Corporation Agent for treatment of bladder troubles
CA2247389C (en) 1996-12-27 2009-11-24 Seikagaku Corporation Agent for treatment of bladder troubles
PT1124546E (pt) * 1998-10-22 2004-08-31 Bioniche Life Sciences Inc Um metodo para prevenir reduzir e tratar a cistite usando acido hialuronico
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
WO2001044465A2 (en) * 1999-12-13 2001-06-21 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
JP4215429B2 (ja) * 1999-12-28 2009-01-28 バイオニケ ライフ サイエンシーズ インコーポレイテッド 癌治療におけるヒアルロン酸
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
JP5731729B2 (ja) * 2005-01-14 2015-06-10 ウーリゲン、インコーポレイテッド 下部尿路障害を治療するためのキット及び改良された組成物
DE102006060953A1 (de) 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
TWI383796B (zh) 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
TWI516269B (zh) 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
HUP0900717A3 (en) 2009-11-18 2012-02-28 Richter Gedeon Nyrt Pharmaceutical composition for urological use containing zinc hyaluronate
US8575130B2 (en) * 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US20110166098A1 (en) * 2010-01-04 2011-07-07 Wu Tsung-Chung Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
ITMI20111732A1 (it) * 2011-09-27 2013-03-28 Bsdpharma Srl Formulazioni farmaceutiche per la riduzione della sensibilizzazione crociata tra colon-retto ed il distretto urogenitale con mezzi non-farmacologici.
RU2519010C1 (ru) * 2013-03-20 2014-06-10 Общество с ограниченной ответственностью "КОЛЕТЕКС" Композиция для лечения цистита
WO2015018461A1 (fr) 2013-08-09 2015-02-12 Genbiotech Compositions therapeutiques comprenant d'acide hyaluronique
CN103655601B (zh) * 2013-12-31 2019-10-25 上海建华精细生物制品有限公司 一种用于膀胱灌洗的组合物
CN103861091B (zh) * 2014-03-20 2016-04-27 辽宁亿灵科创生物医药科技有限公司 治疗膀胱炎的药物组合物
WO2015154007A1 (en) * 2014-04-03 2015-10-08 Lipella Pharmaceuticals, Inc. Systems and methods of detecting interstitial cystitis
RU2557949C1 (ru) * 2014-08-14 2015-07-27 Общество с ограниченной ответственностью "КОЛЕТЕКС" Способ лечения лучевого и интерстициального цистита
EP3400951B1 (de) * 2017-05-12 2019-12-11 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4302577A (en) * 1979-10-05 1981-11-24 Biomed Research Inc. Process for preparing CSA or CSC
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
DE3118588C2 (de) * 1981-05-11 1983-07-07 Luitpold-Werk, Chemisch-Pharmazeutische Fabrik, 8000 München Verfahren zur Herstellung eines injizierbaren hochreinen Chondroitinpolysulfates, hiernach erhältliches Produkt und pharmazeutische Zusammensetzung
US4640912A (en) * 1983-06-09 1987-02-03 Hausman Marvin S Administration of "active" chondroitin sulfate A and "active" chondroitin sulfate C or mixtures thereof to mammals including humans
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US5037810A (en) * 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
DE69329407T2 (de) * 1992-06-02 2001-05-03 Bard Inc C R Verfahren und Implantatvorrichtung für Langzeitwirkstoffabgabe
JP2995090B2 (ja) * 1993-03-19 1999-12-27 キユー・メド・アクチエボラーグ 組織増大のための組成物および方法

Also Published As

Publication number Publication date
TR199700782T1 (xx) 1998-03-21
NO973732L (no) 1997-10-10
HUP9800467A3 (en) 1999-01-28
JP4354528B2 (ja) 2009-10-28
PT813417E (pt) 2003-12-31
US5888986A (en) 1999-03-30
JPH10513476A (ja) 1998-12-22
EP0813417B1 (en) 2003-08-20
CA2203621A1 (en) 1996-08-22
KR19980702251A (ko) 1998-07-15
EP0813417A1 (en) 1997-12-29
DK0813417T3 (da) 2003-11-03
KR100268660B1 (ko) 2000-10-16
MX9706182A (es) 1998-07-31
DE69629553T2 (de) 2004-06-17
DE69629553D1 (de) 2003-09-25
CZ288218B6 (en) 2001-05-16
AU4617996A (en) 1996-09-04
ES2205013T3 (es) 2004-05-01
AU705289B2 (en) 1999-05-20
ATE247476T1 (de) 2003-09-15
NZ300903A (en) 1999-07-29
NO973732D0 (no) 1997-08-13
IN181358B (hu) 1998-05-30
BR9607601A (pt) 1999-09-14
NO315842B1 (no) 2003-11-03
WO1996025168A1 (en) 1996-08-22
CN1181016A (zh) 1998-05-06
CZ257497A3 (cs) 1998-01-14
CA2203621C (en) 1998-04-28

Similar Documents

Publication Publication Date Title
HUP9800467A2 (hu) Hialuronsav alkalmazása szövetközi cisztitisz kezelésére alkalmas gyógyászati készítmények előállítására
EP0637239A4 (en) METHOD FOR PROMOTING NITROGEN RETENTION IN PEOPLE.
DK1123094T3 (da) Terapeutiske præparater (II)
FR2798065B1 (fr) Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
Polson et al. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects.
Snyder et al. Reversal of amitriptyline intoxication by physostigmine
JPH07556B2 (ja) 間質性膀胱炎に対する治療用医薬組成物
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
JP2725994B2 (ja) 抗低酸素症薬および防御薬としてのフタロイルヒドラジド誘導体の使用
Pe et al. Envenoming by Chinese krait (Bungarus multicinctus) and banded krait (B. fasciatus) in Myanmar
AU2001261987A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
JP2002528410A (ja) ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
Pindborg et al. Reiter's syndrome: Review of the literature and report of a case
Wynne-Jones Flatus retention is the major factor in diverticular disease
Levine et al. Fatal water intoxication, schizophrenia, and diuretic therapy for systemic hypertension
RU2230568C1 (ru) Способ лечения флегмон челюстно-лицевой области
Whipple Jr The cure of a patient with a very resistant streptococcus viridans endocarditis with massive penicillin therapy (average daily dose of eighty-six million units)
Behera et al. Dermatomyositosis: a rare case report
Furman et al. Use of Cholinergic Drugs in Paroxysmal Supraventricular Tachycardia: Serious Untoward Reactions and Fatality from Treatment with Methacholine and Neostigmine
WO2002056834A3 (en) Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts
SU1586712A1 (ru) Способ лечени в лотекущих осложнений гонореи
SU1722504A1 (ru) Способ лечени атеросклероза коронарных сосудов
RU1811848C (ru) Способ лечени больных т желой формой шигеллеза
RU2132709C1 (ru) Способ лечения токсических форм дифтерии